Drugs / SP-3164
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05979857 | Mar 2024 → Aug 2025 overdue | non-Hodgkin lymphoma | Salarius Pharmaceuticals, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-3164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05979857 ↗ |
| Route | Oral | “SP-3164 will be administered orally once daily under fasting conditions” NCT05979857 ↗ |